Table 2.

Hazard Ratios between Black and White Patients for Different Survival Outcomes Sequentially Adjusted for Demographic and Clinical Characteristics among 2795 patients

Variables adjusted in model	Hazard Ratio for Black vs. White (95% CI)
	Overall Survival	Recurrence-Free Survival	Breast-Cancer-Specific Survival	Time-to-Recurrence Analysis
Unadjusted	2.14 (1.77–2.58)	1.85 (1.57–2.19)	2.31 (1.76–3.03)	1.51 (1.20–1.91)
Adjusted for age at diagnosis	1.81 (1.50–2.19)	1.69 (1.43–2.00)	2.27 (1.73–2.99)	1.60 (1.27–2.02)
+ stage	1.73 (1.43–2.09)	1.61 (1.36–1.90)	2.08 (1.58–2.74)	1.47 (1.16–1.85)
+ subtype	1.63 (1.34–1.97)	1.51 (1.27–1.79)	1.83 (1.39–2.42)	1.32 (1.04–1.67)
+ grade	1.61 (1.33–1.96)	1.49 (1.26–1.77)	1.81 (1.37–2.40)	1.30 (1.03–1.65)
+ Carlson comorbidity index	1.51 (1.24–1.84)	1.40 (1.18–1.66)	1.78 (1.35–2.36)	1.28 (1.01–1.63)
+ chemotherapy	1.50 (1.24–1.83)	1.39 (1.17–1.66)	1.77 (1.34–2.35)	1.28 (1.01–1.63)
+ radiotherapy	1.53 (1.26–1.86)	1.41 (1.19–1.68)	1.80 (1.36–2.39)	1.29 (1.02–1.64)
+ year at diagnosis	1.53 (1.25–1.86)	1.41 (1.18–1.67)	1.84 (1.39–2.43)	1.28 (1.01–1.63)
+ insurance status	1.35 (1.10–1.66)	1.30 (1.08–1.56)	1.66 (1.23–2.24)	1.23 (0.96–1.59)